Celea Therapeutics
deupirfenidone
idiopathic pulmonary fibrosis
Countdown
86days
Phase 3 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 3 trial results for deupirfenidone in idiopathic pulmonary fibrosis are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 10h ago
“Whilst mindful of macro factors, Celea is targeting to close the financing by early in the third quarter of 2026.”